ClinicalTrials.gg
CompletedNCT00373360Updated Jan 7, 2013Results posted

Safety, Efficacy and Treatment Satisfaction in Patients With PAH Rapidly Switched From Epoprostenol to Remodulin

A Phase 4 interventional study of treprostinil sodium in Pulmonary Hypertension, sponsored by United Therapeutics. Completed at 1 site in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2013-01-07.

Sponsored by United Therapeutics · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
10
Allocation
Non-randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 38 studies testing treprostinil in Hypertension, Pulmonary — 4 open to participants now, 4 under way, 1 of them phase 3. treprostinil · Hypertension, Pulmonary.

Enrollment
26th of 37
10 · median 32
Started
2006
with 2 others
Phase 4
9 of 38
1 open now
Registered
6th of 38
by date
Lead sponsor
25 of 38
United Therapeutics

Among the 38 studies testing treprostinil in Hypertension, Pulmonary, this one is the 26th largest by enrollment of the 37 interventional ones that give a count, is one of 3 that started in 2006, is one of 9 in phase 4, and was the 6th registered.

Hypertension, Pulmonary

1,092 studies on the registry are indexed under Hypertension, Pulmonary; 244 are open to participants now.

Browse Hypertension, Pulmonary studies →

Open to participants now

4 of the 38 studies testing treprostinil in Hypertension, Pulmonary are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About treprostinil

treprostinil: first FDA approval 2002 (REMODULIN), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 164 Hypertension, Pulmonary studies recruiting now, 99 (60%) set no upper age limit and 26 (16%) stop at 75 or younger; 39 take children under 18; 24 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 38 studies testing treprostinil in Hypertension, Pulmonary, or all of them as a file.
02

Study summary

The purpose of this 8-week study is to compare the effects of switching from therapy with epoprostenol or Flolan to IV Remodulin. This study will also assess the effect that changing to Remodulin will have on patient satisfaction with their treatment and impact on quality of life.

Read the detailed description

Pulmonary arterial hypertension (PAH), which is defined as an elevation in pulmonary arterial pressure and pulmonary vascular resistance, is a severe hemodynamic abnormality common to a variety of diseases and syndromes. Elevation in pulmonary arterial pressure causes an increase in right ventricular afterload, impairing right ventricular function and ultimately leading to inactivity and death. The goal of PAH treatment is to lengthen survival time, to ameliorate symptoms of PAH and to improve health related quality of life (HRQOL).

Remodulin® (treprostinil sodium), a stable analogue of prostacyclin, possesses potent pulmonary and systemic vasodilatory and platelet anti-aggregatory actions in vitro and in vivo. Recently, Remodulin received FDA approval for intravenous therapy based upon bioequivalence of the IV and SC routes of administration. Remodulin is more chemically stable than epoprostenol and may offer potential safety and convenience advantages compared to intravenous epoprostenol that may impact Health Related Quality of Life (HRQOL) and/or patient satisfaction. Unlike epoprostenol, Remodulin does not need to be mixed daily and is stable at room temperature eliminating the need for ice packs. Furthermore, since Remodulin remains in the body longer than epoprostenol (4 hrs instead of less than 5 minutes) there is less risk of cardiovascular collapse from a sudden interruption of infusion, such as a line clog. In an open-label study in Europe, patients who were using a type of portable medication pump called the CADD Legacy pump were rapidly switched from Flolan to Remodulin with no serious side effects. This study will examine effects of switching from therapy with epoprostenol or Flolan to IV Remodulin and compare changes in HRQOL and treatment satisfaction before and after rapid switch from epoprostenol to Remodulin in patients with pulmonary hypertension using the CADD legacy pump.

Participation in this study will last approximately 10 weeks. Study procedures include routine blood tests, medical history, physical exams, disease evaluation, exercise tests and patient questionnaires. Participants will have 4 visits during the study and will spend at least 1 night in the hospital.

03

Conditions studied

  • Pulmonary Hypertension

Keywords

  • pulmonary hypertension
  • PAH
  • Remodulin
  • treprostinil
  • Quality of Life
  • Rapid Switch
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 to 70 years
  • Diagnosis of Idiopathic or Familial Pulmonary Arterial Hypertension (PAH)or PAH associated with a collagen vascular disease or PAH associated with congenital systemic-to-pulmonary shunt repaired greater than 5 years prior to study entry or PAH associated with portal hypertension with mild or moderate hepatic dysfunction (Grade of A or B on the Classification Scale)or PAH associated with drug or toxins or CTEPH
  • WHO Class II-III
  • Currently receiving intravenous epoprostenol therapy for at least three months and a stable dose for at least one month.
  • Have central intravenous catheter
  • Optimally treated with conventional pulmonary hypertension therapy and clinically stable for at least one month.
  • Mentally and physically capable of learning to administer Remodulin using an intravenous infusion pump.

Exclusion criteria

Exclusion Criteria:

  • Nursing or pregnant woman
  • Have any other type of PAH due to conditions other than noted in the above inclusion criteria, including but not limited to PAH related to thrombotic or embolic disease
  • Have any other disease that is associated with pulmonary hypertension (e.g. sickle cell anemia, schistosomiasis)
  • Changes to chronic PAH therapy (i.e., new therapy added within last 30 days[including but not limited to oxygen, a different category of vasodilator, a diuretic, digoxin, bosentan, sildenafil] or PAH medication discontinued within 7 days of study entry.
  • Received any prostacyclin or prostacyclin analog except epoprostenol in the past 3 months.
  • Central venous line infection within the past 30 days.
  • Previous documented evidence of significant parenchymal lung disease
  • Evidence or history of left-sided heart disease
  • Musculoskeletal disorder or any other disease, which is thought to limit ambulation, or be connected to a machine that is not portable
  • Uncontrolled hypertension, chronic renal insufficiency, or active infection.
  • Use of drug within past 30 days.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (actual)

Study arms

  • Experimental
    1

    Drug: treprostinil sodium

Interventions

  • rapid switch from intravenous epoprostinol to intravenous remodulin on the CADD ambulatory pump

    Also known as: Remodulin, Flolan

06

What researchers measure

Primary outcomes

  1. Change in the Distance Transversed During the 6 Minute Walk Test From Baseline to Week 8.

    Time frame: Baseline and Week 8

Secondary outcomes

  1. Change in Borg Dyspnea Score Immediately After Six Minute Walk Test From Baseline to Week 8

    The Borg dyspnea score is a 10-point scale rating the maximum level of dyspnea experienced during the 6-minute walk test. The Borg dyspnea score was assessed immediately following the 6-minute walk test. Scores ranged from 0 (for no shortness of breath) to 10 (for greatest shortness of breath ever experienced).

    Time frame: Baseline and Week 8

  2. Change in World Health Organization (WHO) Functional Classification of PAH From Baseline to Week 8

    Class I: Patients with pulmonary hypertension but without resulting limitation of physical activity. Ordinary physical activity does not cause undue dyspnea or fatigue, chest pain, or near syncope. Class II: Patients with pulmonary hypertension resulting in slight limitation of physical activity. These patients are comfortable at rest, but ordinary physical activity causes undue dyspnea or fatigue, chest pain or near syncope. Class III: Patients with pulmonary hypertension resulting in marked limitation of physical activity. They are comfortable at rest. Ordinary activity causes undue dyspnea or fatigue, chest pain, or near syncope. Class IV: Patients with pulmonary hypertension with inability to carry out any physical activity without symptoms. These patients manifest signs of right heart failure. Dyspnea and/or fatigue may be present even at rest. Discomfort is increased by any physical activity.

    Time frame: Baseline and Week 8

  3. Change in Symptoms of Dyspnea From Baseline to Week 8

    The presence or absence of dyspnea was documented. If present, the intensity of dyspnea was rated mild, moderate, or severe.

    Time frame: Baseline and Week 8

  4. Change in Symptoms of Edema From Baseline to Week 8

    The presence or absence of edema was documented. If present, the intensity of edema was rated mild, moderate, or severe.

    Time frame: Baseline to Week 8

  5. Change in Symptoms of Orthopnea From Baseline to Week 8

    The presence or absence of orthopnea was documented. If present, the intensity of orthopnea was rated mild, moderate, or severe.

    Time frame: Baseline and Week 8

  6. Change in Symptoms of Dizziness From Baseline to Week 8

    The presence or absence of dizziness was documented. If present, the intensity of dizziness was rated mild, moderate, or severe.

    Time frame: Baseline and Week 8

  7. Change in Symptoms of Fatigue From Baseline to Week 8

    The presence or absence of fatigue was documented. If present, the intensity of fatigue was rated mild, moderate, or severe.

    Time frame: Baseline and Week 8

  8. Change in Symptoms of Syncope From Baseline to Week 8

    The presence or absence of syncope was documented. If present, the intensity of syncope was rated mild, moderate, or severe.

    Time frame: Baseline and Week 8

  9. Change in Symptoms of Chest Pain From Baseline to Week 8

    The presence or absence of chest pain was documented. If present, the intensity of chest pain was rated mild, moderate, or severe.

    Time frame: Baseline and Week 8

  10. Change in Effectiveness Score on Treatment Satisfaction Scale From Baseline to Week 8

    The Treatment Satisfaction Questionnaire for Medication (TSQM) is a validated instrument that measures four major dimensions of patient satisfaction with medications: effectiveness, side effects, convenience, and global satisfaction. TSQM Scale scores are computed by adding the items loading on each factor. The lowest possible score is subtracted from this composite score and divided by the greatest possible score minus the lowest possible score. This provided a transformed score between 0 and 1 that should be multiplied by 100 (scale 0-100). A low score indicates low satisfaction and a high score indicates high satisfaction with treatment.

    Time frame: Baseline and Week 8

  11. Change in Side-Effects Score on Treatment Satisfaction Scale From Baseline to Week 8

    The Treatment Satisfaction Questionnaire for Medication (TSQM) is a validated instrument that measures four major dimensions of patient satisfaction with medications: effectiveness, side effects, convenience, and global satisfaction. TSQM Scale scores are computed by adding the items loading on each factor. The lowest possible score is subtracted from this composite score and divided by the greatest possible score minus the lowest possible score. This provided a transformed score between 0 and 1 that should be multiplied by 100 (scale 0-100). A low score indicates low satisfaction and a high score indicates high satisfaction with treatment.

    Time frame: Baseline and Week 8

  12. Change in Convenience Score on Treatment Satisfaction Scale From Baseline to Week 8

    The Treatment Satisfaction Questionnaire for Medication (TSQM) is a validated instrument that measures four major dimensions of patient satisfaction with medications: effectiveness, side effects, convenience, and global satisfaction. TSQM Scale scores are computed by adding the items loading on each factor. The lowest possible score is subtracted from this composite score and divided by the greatest possible score minus the lowest possible score. This provided a transformed score between 0 and 1 that should be multiplied by 100 (scale 0-100). A low score indicates low satisfaction and a high score indicates high satisfaction with treatment.

    Time frame: Baseline and Week 8

  13. Change in Global Satisfaction Score on Treatment Satisfaction Scale From Baseline to Week 8

    The Treatment Satisfaction Questionnaire for Medication (TSQM) is a validated instrument that measures four major dimensions of patient satisfaction with medications: effectiveness, side effects, convenience, and global satisfaction. TSQM Scale scores are computed by adding the items loading on each factor. The lowest possible score is subtracted from this composite score and divided by the greatest possible score minus the lowest possible score. This provided a transformed score between 0 and 1 that should be multiplied by 100 (scale 0-100). A low score indicates low satisfaction and a high score indicates high satisfaction with treatment.

    Time frame: Baseline and Week 8

  14. Change in Total Score on Quality of Life Questionnaire From Baseline to Week 8

    The Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR) is a health related quality of life instrument specific to PAH. The total score can range from 0 -75; the higher the score, the worse the outcome.

    Time frame: Baseline and Week 8

  15. Change in Patient Impression of Change in Symptoms of PAH From Baseline to Week 8

    Subjects were asked to compare their symptoms of PAH as compared to 8 weeks prior and rate as much better, somewhat better, about the same, somewhat worse, or much worse.

    Time frame: Baseline and Week 8

  16. Change in Patient Impression of Change on Time Spent Dealing With Therapy From Baseline to Week 8

    Subjects were asked to compare their previous experience with Flolan and rate how much time was spent dealing with intravenous Remodulin therapy as much less, somewhat less, about the same, somewhat more, or much more.

    Time frame: Baseline and Week 8

  17. Change in Patient Impression of Change of Satisfaction With Therapy From Baseline to Week 8

    Subjects were asked to compare their previous experience with Flolan and rate satisfaction with intravenous Remodulin therapy over the past two weeks as much more satisfied, more satisfied, about the same, less satisfied, or much less satisfied.

    Time frame: Baseline and Week 8

  18. Change in Total Weekly Time Spent to Gather/Set-up Materials Associated With Intravenous Remodulin Therapy Compared to Same Activities With Intravenous Epoprostenol

    Time frame: Baseline and Week 8

  19. Change in Total Weekly Time Spent to Connect Drug With Intravenous Remodulin Therapy Compared to Same Activities With Intravenous Epoprostenol

    Time frame: Baseline and Week 8

  20. Change in Total Weekly Time Spent to Change Dressing With Intravenous Remodulin Therapy Compared to Same Activities With Intravenous Epoprostenol

    Time frame: Baseline and Week 8

  21. Change in Total Weekly Time Spent to Prepare Drug With Intravenous Remodulin Therapy Compared to Same Activities With Intravenous Epoprostenol

    Time frame: Baseline and Week 8

  22. Change in Total Number of Times Daily Required to Disconnect Infusion Pump With Intravenous Remodulin Therapy Compared to Same Activities With Intravenous Epoprostenol

    Time frame: Baseline and Week 8

  23. Change in Total Number of Times Daily Required to Check Infusion Pump With Intravenous Remodulin Therapy Compared to Same Activities With Intravenous Epoprostenol

    Time frame: Baseline and Week 8

  24. Change in Total Number of Times Daily Infusion Pump Alarms With Intravenous Remodulin Therapy Compared to Same Activities With Intravenous Epoprostenol

    Time frame: Baseline and Week 8

07

Results

Posted Jan 7, 2013

Participant flow

Subject participated in this study between July 2007 and January 2008.

Participant flow — Overall Study
MilestoneTreprostinil Sodium
Started10
Completed10
Not completed0

Outcome measures

PrimaryChange in the Distance Transversed During the 6 Minute Walk Test From Baseline to Week 8.
Time frame:
Baseline and Week 8
Reported as:
Mean · meters
Change in the Distance Transversed During the 6 Minute Walk Test From Baseline to Week 8.
metersTreprostinil Sodium
Change in the Distance Transversed During the 6 Minute Walk Test From Baseline to Week 8.-2.2 ± 34.8
Statistical analysis
  • Treprostinil Sodium · Wilcoxon signed rank test · p = 1.000
SecondaryChange in Borg Dyspnea Score Immediately After Six Minute Walk Test From Baseline to Week 8

The Borg dyspnea score is a 10-point scale rating the maximum level of dyspnea experienced during the 6-minute walk test. The Borg dyspnea score was assessed immediately following the 6-minute walk test. Scores ranged from 0 (for no shortness of breath) to 10 (for greatest shortness of breath ever experienced).

Time frame:
Baseline and Week 8
Reported as:
Mean · units on a scale
Change in Borg Dyspnea Score Immediately After Six Minute Walk Test From Baseline to Week 8
units on a scaleTreprostinil Sodium
Change in Borg Dyspnea Score Immediately After Six Minute Walk Test From Baseline to Week 81.56 ± 0.98
Statistical analysis
  • Treprostinil Sodium · Wilcoxon signed rank test · p = 0.008
SecondaryChange in World Health Organization (WHO) Functional Classification of PAH From Baseline to Week 8

Class I: Patients with pulmonary hypertension but without resulting limitation of physical activity. Ordinary physical activity does not cause undue dyspnea or fatigue, chest pain, or near syncope. Class II: Patients with pulmonary hypertension resulting in slight limitation of physical activity. These patients are comfortable at rest, but ordinary physical activity causes undue dyspnea or fatigue, chest pain or near syncope. Class III: Patients with pulmonary hypertension resulting in marked limitation of physical activity. They are comfortable at rest. Ordinary activity causes undue dyspnea or fatigue, chest pain, or near syncope. Class IV: Patients with pulmonary hypertension with inability to carry out any physical activity without symptoms. These patients manifest signs of right heart failure. Dyspnea and/or fatigue may be present even at rest. Discomfort is increased by any physical activity.

Time frame:
Baseline and Week 8
Reported as:
Number · percentage of participants
Change in World Health Organization (WHO) Functional Classification of PAH From Baseline to Week 8
percentage of participantsTreprostinil Sodium
Improved11
No Change89
Worsened0
Statistical analysis
  • Treprostinil Sodium · Wilcoxon signed rank test · p = 1.000
SecondaryChange in Symptoms of Dyspnea From Baseline to Week 8

The presence or absence of dyspnea was documented. If present, the intensity of dyspnea was rated mild, moderate, or severe.

Time frame:
Baseline and Week 8
Reported as:
Number · percentage of participants
Change in Symptoms of Dyspnea From Baseline to Week 8
percentage of participantsTreprostinil Sodium
Improved22
No Change33
Worsened44
Statistical analysis
  • Treprostinil Sodium · Wilcoxon signed rank test · p = 0.531
SecondaryChange in Symptoms of Edema From Baseline to Week 8

The presence or absence of edema was documented. If present, the intensity of edema was rated mild, moderate, or severe.

Time frame:
Baseline to Week 8
Reported as:
Number · percentage of participants
Change in Symptoms of Edema From Baseline to Week 8
percentage of participantsTreprostinil Sodium
Improved22
No Change56
Worsened22
Statistical analysis
  • Treprostinil Sodium · Wilcoxon signed rank test · p = 1.000
SecondaryChange in Symptoms of Orthopnea From Baseline to Week 8

The presence or absence of orthopnea was documented. If present, the intensity of orthopnea was rated mild, moderate, or severe.

Time frame:
Baseline and Week 8
Reported as:
Number · percentage of participants
Change in Symptoms of Orthopnea From Baseline to Week 8
percentage of participantsTreprostinil Sodium
Improved22
No Change78
Worsened0
Statistical analysis
  • Treprostinil Sodium · Wilcoxon signed rank test · p = 0.500
SecondaryChange in Symptoms of Dizziness From Baseline to Week 8

The presence or absence of dizziness was documented. If present, the intensity of dizziness was rated mild, moderate, or severe.

Time frame:
Baseline and Week 8
Reported as:
Number · percentage of participants
Change in Symptoms of Dizziness From Baseline to Week 8
percentage of participantsTreprostinil Sodium
Improved11
No Change89
Worsened0
Statistical analysis
  • Treprostinil Sodium · Wilcoxon signed rank test · p = 1.000
SecondaryChange in Symptoms of Fatigue From Baseline to Week 8

The presence or absence of fatigue was documented. If present, the intensity of fatigue was rated mild, moderate, or severe.

Time frame:
Baseline and Week 8
Reported as:
Number · percentage of participants
Change in Symptoms of Fatigue From Baseline to Week 8
percentage of participantsTreprostinil Sodium
Improved22
No Change67
Worsened11
Statistical analysis
  • Treprostinil Sodium · Wilcoxon signed rank test · p = 1.000
SecondaryChange in Symptoms of Syncope From Baseline to Week 8

The presence or absence of syncope was documented. If present, the intensity of syncope was rated mild, moderate, or severe.

Time frame:
Baseline and Week 8
Reported as:
Number · percentage of participants
Change in Symptoms of Syncope From Baseline to Week 8
percentage of participantsTreprostinil Sodium
Improved0
No Change100
Worsened0
Statistical analysis
  • Treprostinil Sodium · Wilcoxon signed rank test · p = 0
SecondaryChange in Symptoms of Chest Pain From Baseline to Week 8

The presence or absence of chest pain was documented. If present, the intensity of chest pain was rated mild, moderate, or severe.

Time frame:
Baseline and Week 8
Reported as:
Number · percentage of participants
Change in Symptoms of Chest Pain From Baseline to Week 8
percentage of participantsTreprostinil Sodium
Improved0
No Change89
Worsened11
Statistical analysis
  • Treprostinil Sodium · Wilcoxon signed rank test · p = 1.000
SecondaryChange in Effectiveness Score on Treatment Satisfaction Scale From Baseline to Week 8

The Treatment Satisfaction Questionnaire for Medication (TSQM) is a validated instrument that measures four major dimensions of patient satisfaction with medications: effectiveness, side effects, convenience, and global satisfaction. TSQM Scale scores are computed by adding the items loading on each factor. The lowest possible score is subtracted from this composite score and divided by the greatest possible score minus the lowest possible score. This provided a transformed score between 0 and 1 that should be multiplied by 100 (scale 0-100). A low score indicates low satisfaction and a high score indicates high satisfaction with treatment.

Time frame:
Baseline and Week 8
Reported as:
Mean · units on a scale
Change in Effectiveness Score on Treatment Satisfaction Scale From Baseline to Week 8
units on a scaleTreprostinil Sodium
Effectiveness Score at Baseline71.6 ± 29.2
Effectiveness Score at Week 882.7 ± 23.1
Statistical analysis
  • Treprostinil Sodium · Wilcoxon signed rank test · p = 0.031
SecondaryChange in Side-Effects Score on Treatment Satisfaction Scale From Baseline to Week 8

The Treatment Satisfaction Questionnaire for Medication (TSQM) is a validated instrument that measures four major dimensions of patient satisfaction with medications: effectiveness, side effects, convenience, and global satisfaction. TSQM Scale scores are computed by adding the items loading on each factor. The lowest possible score is subtracted from this composite score and divided by the greatest possible score minus the lowest possible score. This provided a transformed score between 0 and 1 that should be multiplied by 100 (scale 0-100). A low score indicates low satisfaction and a high score indicates high satisfaction with treatment.

Time frame:
Baseline and Week 8
Reported as:
Mean · units on a scale
Change in Side-Effects Score on Treatment Satisfaction Scale From Baseline to Week 8
units on a scaleTreprostinil Sodium
Side Effects Score at Baseline71.5 ± 14.4
Side Effects Score at Week 884.7 ± 12.1
Statistical analysis
  • Treprostinil Sodium · Wilcoxon signed rank test · p = 0.031
SecondaryChange in Convenience Score on Treatment Satisfaction Scale From Baseline to Week 8

The Treatment Satisfaction Questionnaire for Medication (TSQM) is a validated instrument that measures four major dimensions of patient satisfaction with medications: effectiveness, side effects, convenience, and global satisfaction. TSQM Scale scores are computed by adding the items loading on each factor. The lowest possible score is subtracted from this composite score and divided by the greatest possible score minus the lowest possible score. This provided a transformed score between 0 and 1 that should be multiplied by 100 (scale 0-100). A low score indicates low satisfaction and a high score indicates high satisfaction with treatment.

Time frame:
Baseline and Week 8
Reported as:
Mean · units on a scale
Change in Convenience Score on Treatment Satisfaction Scale From Baseline to Week 8
units on a scaleTreprostinil Sodium
Convenience Score at Baseline59.9 ± 14.4
Convenience Score at Week 890.7 ± 10.8
Statistical analysis
  • Treprostinil Sodium · Wilcoxon signed rank test · p = 0.004
SecondaryChange in Global Satisfaction Score on Treatment Satisfaction Scale From Baseline to Week 8

The Treatment Satisfaction Questionnaire for Medication (TSQM) is a validated instrument that measures four major dimensions of patient satisfaction with medications: effectiveness, side effects, convenience, and global satisfaction. TSQM Scale scores are computed by adding the items loading on each factor. The lowest possible score is subtracted from this composite score and divided by the greatest possible score minus the lowest possible score. This provided a transformed score between 0 and 1 that should be multiplied by 100 (scale 0-100). A low score indicates low satisfaction and a high score indicates high satisfaction with treatment.

Time frame:
Baseline and Week 8
Reported as:
Mean · units on a scale
Change in Global Satisfaction Score on Treatment Satisfaction Scale From Baseline to Week 8
units on a scaleTreprostinil Sodium
Global Satisfaction Score at Baseline84.1 ± 15.1
Global Satisfaction Score at Week 892.1 ± 14.0
Statistical analysis
  • Treprostinil Sodium · Wilcoxon signed rank test · p = 0.063
SecondaryChange in Total Score on Quality of Life Questionnaire From Baseline to Week 8

The Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR) is a health related quality of life instrument specific to PAH. The total score can range from 0 -75; the higher the score, the worse the outcome.

Time frame:
Baseline and Week 8
Reported as:
Mean · units on a scale
Change in Total Score on Quality of Life Questionnaire From Baseline to Week 8
units on a scaleTreprostinil Sodium
CAMPHOR score at Baseline18.9 ± 12.5
CAMPHOR score at Week 812.9 ± 10.8
Statistical analysis
  • Treprostinil Sodium · Wilcoxon signed rank test · p = 0.203
SecondaryChange in Patient Impression of Change in Symptoms of PAH From Baseline to Week 8

Subjects were asked to compare their symptoms of PAH as compared to 8 weeks prior and rate as much better, somewhat better, about the same, somewhat worse, or much worse.

Time frame:
Baseline and Week 8
Reported as:
Number · participants
Change in Patient Impression of Change in Symptoms of PAH From Baseline to Week 8
participantsTreprostinil Sodium
Much better5
Somewhat better1
About the same3
Somewhat worse0
Much worse0
SecondaryChange in Patient Impression of Change on Time Spent Dealing With Therapy From Baseline to Week 8

Subjects were asked to compare their previous experience with Flolan and rate how much time was spent dealing with intravenous Remodulin therapy as much less, somewhat less, about the same, somewhat more, or much more.

Time frame:
Baseline and Week 8
Reported as:
Number · participants
Change in Patient Impression of Change on Time Spent Dealing With Therapy From Baseline to Week 8
participantsTreprostinil Sodium
Much less8
Somewhat Less0
About the same1
Somewhat more0
Much more0
SecondaryChange in Patient Impression of Change of Satisfaction With Therapy From Baseline to Week 8

Subjects were asked to compare their previous experience with Flolan and rate satisfaction with intravenous Remodulin therapy over the past two weeks as much more satisfied, more satisfied, about the same, less satisfied, or much less satisfied.

Time frame:
Baseline and Week 8
Reported as:
Number · participants
Change in Patient Impression of Change of Satisfaction With Therapy From Baseline to Week 8
participantsTreprostinil Sodium
Much more satisfied7
More satisfied2
About the same0
Less satisfied0
Much less satisfied0
SecondaryChange in Total Weekly Time Spent to Gather/Set-up Materials Associated With Intravenous Remodulin Therapy Compared to Same Activities With Intravenous Epoprostenol
Time frame:
Baseline and Week 8
Reported as:
Mean · minutes
Change in Total Weekly Time Spent to Gather/Set-up Materials Associated With Intravenous Remodulin Therapy Compared to Same Activities With Intravenous Epoprostenol
minutesTreprostinil Sodium
Time to gather/set up epoprostenol at Baseline34.9 ± 28.7
Time to gather/set up Remodulin at Week 827.0 ± 28.7
Statistical analysis
  • Treprostinil Sodium · Wilcoxon signed rank test · p = 0.250
SecondaryChange in Total Weekly Time Spent to Connect Drug With Intravenous Remodulin Therapy Compared to Same Activities With Intravenous Epoprostenol
Time frame:
Baseline and Week 8
Reported as:
Mean · minutes
Change in Total Weekly Time Spent to Connect Drug With Intravenous Remodulin Therapy Compared to Same Activities With Intravenous Epoprostenol
minutesTreprostinil Sodium
Time spent to connect epoprostenol at Baseline23.2 ± 14.4
Time spent to connect Remodulin at Week 818.7 ± 13.9
Statistical analysis
  • Treprostinil Sodium · Wilcoxon signed rank test · p = 0.207
SecondaryChange in Total Weekly Time Spent to Change Dressing With Intravenous Remodulin Therapy Compared to Same Activities With Intravenous Epoprostenol
Time frame:
Baseline and Week 8
Reported as:
Mean · minutes
Change in Total Weekly Time Spent to Change Dressing With Intravenous Remodulin Therapy Compared to Same Activities With Intravenous Epoprostenol
minutesTreprostinil Sodium
Time to change dressing with epoprostenol at BL31.4 ± 14.2
Time to change dressing with Remdoluin at Wk 828.6 ± 25.8
Statistical analysis
  • Treprostinil Sodium · Wilcoxon signed rank test · p = 0.297
SecondaryChange in Total Weekly Time Spent to Prepare Drug With Intravenous Remodulin Therapy Compared to Same Activities With Intravenous Epoprostenol
Time frame:
Baseline and Week 8
Reported as:
Mean · minutes
Change in Total Weekly Time Spent to Prepare Drug With Intravenous Remodulin Therapy Compared to Same Activities With Intravenous Epoprostenol
minutesTreprostinil Sodium
Time to prepare epoprostenol at Baseline109.0 ± 61.0
Time to prepare Remodulin at Week 847.8 ± 31.6
Statistical analysis
  • Treprostinil Sodium · Wilcoxon signed rank test · p = 0.004
SecondaryChange in Total Number of Times Daily Required to Disconnect Infusion Pump With Intravenous Remodulin Therapy Compared to Same Activities With Intravenous Epoprostenol
Time frame:
Baseline and Week 8
Reported as:
Mean · number of times per day
Change in Total Number of Times Daily Required to Disconnect Infusion Pump With Intravenous Remodulin Therapy Compared to Same Activities With Intravenous Epoprostenol
number of times per dayTreprostinil Sodium
Disconnect pump at Baseline (epoprostenol)7.7 ± 5.3
Disconnect pump at Wk 8 (Remodulin)4.1 ± 1.9
SecondaryChange in Total Number of Times Daily Required to Check Infusion Pump With Intravenous Remodulin Therapy Compared to Same Activities With Intravenous Epoprostenol
Time frame:
Baseline and Week 8
Reported as:
Mean · number of times per day
Change in Total Number of Times Daily Required to Check Infusion Pump With Intravenous Remodulin Therapy Compared to Same Activities With Intravenous Epoprostenol
number of times per dayTreprostinil Sodium
Check pump at Baseline (epoprostenol)19.2 ± 11.5
Check pump at Week 8 (Remodulin)12.2 ± 8.9
SecondaryChange in Total Number of Times Daily Infusion Pump Alarms With Intravenous Remodulin Therapy Compared to Same Activities With Intravenous Epoprostenol
Time frame:
Baseline and Week 8
Reported as:
Mean · number of times per day
Change in Total Number of Times Daily Infusion Pump Alarms With Intravenous Remodulin Therapy Compared to Same Activities With Intravenous Epoprostenol
number of times per dayTreprostinil Sodium
Daily alarms at Baseline (epoprostenol)2.4 ± 3.3
Daily alarms at Week 8 (Remodulin)0.8 ± 1.1

Adverse events

Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Treprostinil Sodium—2/10 (20%)9/10 (90%)
Most frequent serious events
Most frequent serious events
EventTreprostinil Sodium
GastroenteritisGastrointestinal disorders2/10
Most frequent other events
Showing 10 of 14
Most frequent other events
EventTreprostinil Sodium
Pain in extremityMusculoskeletal and connective tissue disorders5/10
HeadacheGeneral disorders2/10
Restless Leg SyndromeNervous system disorders2/10
Atrial fibrillationCardiac disorders1/10
DiarrheaGastrointestinal disorders1/10
Hand fractureMusculoskeletal and connective tissue disorders1/10
Injection site erythemaSkin and subcutaneous tissue disorders1/10
Muscle spasmsMusculoskeletal and connective tissue disorders1/10
NauseaGastrointestinal disorders1/10
Peripheral edemaVascular disorders1/10

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Treprostinil Sodium
<=18 years0
Between 18 and 65 years8
>=65 years2
Sex: Female, Male
Sex: Female, Male(Participants)Treprostinil Sodium
Female8
Male2
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Treprostinil Sodium
Hispanic or Latino0
Not Hispanic or Latino10
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Treprostinil Sodium
American Indian or Alaska Native1
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American3
White6
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(participants)Treprostinil Sodium
United States10
PAH Etiology
PAH Etiology(participants)Treprostinil Sodium
Idiopathic PAH7
Connective Tissue Disease (CTD)2
Other1
World Health Organization (WHO) Functional Classification for PAH
World Health Organization (WHO) Functional Classification for PAH(participants)Treprostinil Sodium
Class II6
Class III4
Six minute walk distance
Six minute walk distance(meters)Treprostinil Sodium
Mean447.7 (195 to 663)

1 further baseline measures are reported on the registry.

08

Study locations

1 site
  • Cleveland Clinic Foundation
    Cleveland, Ohio 44195, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2006, a primary completion of Jan 2008 and a completion of Jan 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2013, 5 years after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 7, 2006
First posted
Sep 8, 2006
Start
Sep 2006
Primary completionActual
Jan 2008
CompletionActual
Jan 2008
Results first posted
Jan 7, 2013
Last update
Jan 7, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 7, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00373360
Responsible party
Sponsor
First posted
Sep 8, 2006
Start date
Sep 2006
Primary completion
Jan 2008
Completion
Jan 2008
Results posted
Jan 7, 2013
Last update
Jan 7, 2013

Study contacts

Omar Minai, MD
principal investigator · The Cleveland Clinic

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Treprostinil

Start the discussion